Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

NCT03829449 is registered in ClinicalTrials.gov with AKARI Therapeutics as lead sponsor.

NCT NCT03829449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03829449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
Lead sponsor
AKARI Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
March 13, 2017
Completion date
August 29, 2020
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal nocturnal hemoglobinuria